SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Часто задаваемые вопросы
В каком секторе работает SQZ Biotechnologies Company (SQZB)?
SQZ Biotechnologies Company относится к сектору Здравоохранение.
Какова текущая цена акций SQZ Biotechnologies Company (SQZB)?
По последним данным, цена акций SQZ Biotechnologies Company составляет 0,02 $, предыдущее закрытие — 0,02 $.
Выплачивает ли SQZ Biotechnologies Company (SQZB) дивиденды?
Нет, SQZ Biotechnologies Company не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у SQZ Biotechnologies Company (SQZB)?
У компании SQZ Biotechnologies Company бета 0.383, что указывает на более низкую волатильность по сравнению с рынком в целом.
